
Double trouble! Congrats to @RoshalPatel on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! @MSK_RadOnc @MSKCancerCenter #18ICML
✓Radiation Oncology Resident @MSK_RadOnc

Double trouble! Congrats to @RoshalPatel on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! @MSK_RadOnc @MSKCancerCenter #18ICML

Beyond proud of our @MSK_RadOnc hematology research team! Exciting research at the forefront of all aspects of #18ICML!! Hopefully the Lago view makes up for all the hard work 😉 @MSKCancerCenter

Amazing work @fregonese_bea presenting our initial results on financial toxicity and decision regret in #aya #hodgkinlymphoma survivors. There’s still time for patients to fill out the survey: bit.ly/3SLZ0ke


V relevant given newly-finalized guidance from @FDAOncology, these are potentially actionable changes in trial eligibility criteria to address age disparities. Highlighted in @ScienceMagazine science.org/content/article/…. Excellent work by @roshalp & co! @cd_fuller @geriradonc

These data support recent ASCO and FDA guidelines suggesting that patients with previous cancers with limited potential to affect safety/efficacy assessment should be included in trials asco.org/research-data/clini…

-Prior malignancy exclusion criteria are widely utilized among cancer trials -Longer exclusionary timeframes may worsen age disparities affecting older patient enrollment into trials -Broadening eligibility criteria can improve generalizability and increase trial enrollment

Eligibility criteria in #cancer clinical trials that exclude patients with prior malignancies may independently contribute to age disparities @ebludmir @Cancers_MDPI mdpi.com/2072-6694/14/4/1048